HilleVax (NASDAQ:HLVX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect HilleVax to post earnings of ($0.14) per share for the quarter.
HilleVax (NASDAQ:HLVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. On average, analysts expect HilleVax to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
HilleVax Stock Up 0.5%
NASDAQ:HLVX traded up $0.01 on Friday, hitting $2.07. The stock had a trading volume of 112,818 shares, compared to its average volume of 805,548. The business's 50-day simple moving average is $2.02 and its two-hundred day simple moving average is $1.87. HilleVax has a 52-week low of $1.34 and a 52-week high of $2.17. The stock has a market cap of $103.79 million, a price-to-earnings ratio of -1.45 and a beta of 0.77.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in HilleVax stock. AQR Capital Management LLC lifted its stake in HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 38.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,495 shares of the company's stock after buying an additional 9,228 shares during the quarter. AQR Capital Management LLC owned about 0.07% of HilleVax worth $49,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 86.42% of the company's stock.
About HilleVax
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Further Reading
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access